Overview

Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cSSSI

Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
Tigecycline's activity against resistant organisms, as well as significant coverage of both gram-positive and gram-negative bacteria, may provide a valuable therapeutic alternative in treating patients with complicated skin and/or skin structure infections.
Phase:
Phase 4
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Minocycline
Tigecycline